AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2018
Exchange: NASDAQ
Website: avrobio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2023 | Buy → Neutral | Mizuho | |
| 1/6/2022 | $28.00 → $6.00 | Buy | Mizuho |
| 1/5/2022 | $22.00 → $6.00 | Overweight | Barclays |
| 1/5/2022 | $7.00 → $3.00 | Equal-Weight | Morgan Stanley |
| 1/5/2022 | Buy → Neutral | BTIG | |
| 1/5/2022 | $28.00 → $8.00 | Buy | Needham |
| 11/19/2021 | $24.00 → $7.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/12/2021 | $27.00 → $25.00 | Overweight | Morgan Stanley |
| 7/16/2021 | $31.00 → $29.00 | Overweight | Morgan Stanley |
4 - AVROBIO, Inc. (0001681087) (Issuer)
Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str
Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on promising initial Phase 1A data; confirmatory Phase 1A data expected mid-2024 and topline Phase 1B data expected in 2025 Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced the initiation of enrollment in the Phase 1B study for TX45, an investigational long-acting relaxin-Fc fu
Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March: TD Cowen 44th Annual Health Care Conference being held in Boston on March 4 – 6 Leerink Partners Global Biopharma Conference being held in Miami on March 11 – 13 The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink rep
Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic's novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company expected to have approximately $165 million in cash and cash equivalents at close to provide cash runway into mid-2027 Funding is expected to advance lead asset TX45, a potential best-in-class Fc-relaxin fusion protein, through multiple clinical data catalysts Tectonic's first two programs address indications with high unmet need and no approved therapies Companies to host joint webcast to
AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. AVROBIO has made the determination to halt further development of its programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. As part of this evaluation process, AVROBIO will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction. There can be no assurance that its explorat
All-cash transaction, full $87.5 million paid at closing Proceeds expected to extend cash runway into Q4 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the closing of the previously announced agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for cystinosis to Novartis for $87.5 million in cash. AVROBIO retains full rights to its portfolio of first-in-class HSC gene therapies for Gaucher disease type 1 and type 3, Hunter syndrome and Pompe disease. Proceeds from this transaction are expected to extend the Company's cash runway into the fourt
All-cash transaction, with full $87.5 million to be paid at closing Proceeds expected to extend cash runway into Q4 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an agreement to sell its investigational hematopoietic stem cell (HSC) gene therapy program for the treatment of cystinosis to Novartis for $87.5 million in cash. AVROBIO retains full rights to its portfolio of first-in-class HSC gene therapies for Gaucher disease type 1 and type 3, Hunter syndrome and Pompe disease. Proceeds from this transaction are expected to extend the Company's cash runway into the fourth quarter o
All patients remain off oral cysteamine up to 36 months post gene therapy Sustained engraftment and durable reduction in leukocyte cystine levels across all patients Received positive regulatory feedback from US and UK agencies AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced follow-up data demonstrating a durable treatment effect across key measures out to 36 months from a collaborator-sponsored Phase 1/2 clinical trial1 evaluating an investigational gene therapy for the treatment of cystinosis. These data are being presented at the 26th Annual Meeting of the American Society of Gene
On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to initiate late-stage cystinosis clinical trial activities in second half 2023, subject to regulatory alignment Collaborator-sponsored Phase 1/2 clinical trial for mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, initiated Announced appointment of current CFO Erik Ostrowski as interim CEO AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a l
Current CFO Erik Ostrowski named interim CEO, replacing Founding President and CEO Geoff MacKay AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the appointment of Erik Ostrowski as interim Chief Executive Officer effective as of today. Mr. Ostrowski, who will continue as AVROBIO's Chief Financial Officer, succeeds founding President and CEO Geoff MacKay, who is leaving to join an emerging early-stage company. The Board of Directors has begun a search to identify a permanent CEO. "On behalf of the entire board and the AVROBIO team, we thank Geoff for his eight-year commitment, building a
Mizuho downgraded AVROBIO from Buy to Neutral
Mizuho reiterated coverage of Avrobio with a rating of Buy and set a new price target of $6.00 from $28.00 previously
Barclays reiterated coverage of Avrobio with a rating of Overweight and set a new price target of $6.00 from $22.00 previously
Morgan Stanley reiterated coverage of Avrobio with a rating of Equal-Weight and set a new price target of $3.00 from $7.00 previously
BTIG downgraded Avrobio from Buy to Neutral
Needham reiterated coverage of Avrobio with a rating of Buy and set a new price target of $8.00 from $28.00 previously
Morgan Stanley downgraded AVROBIO from Overweight to Equal-Weight and set a new price target of $7.00 from $24.00 previously
Morgan Stanley reiterated coverage of Avrobio with a rating of Overweight and set a new price target of $25.00 from $27.00 previously
Morgan Stanley reiterated coverage of Avrobio with a rating of Overweight and set a new price target of $29.00 from $31.00 previously
BTIG initiated coverage of Avrobio with a rating of Buy and set a new price target of $23.00
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
3 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
3 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
3 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
3 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
8-K/A - AVROBIO, Inc. (0001681087) (Filer)
8-K - AVROBIO, Inc. (0001681087) (Filer)
8-K - AVROBIO, Inc. (0001681087) (Filer)
425 - AVROBIO, Inc. (0001681087) (Subject)
8-K - AVROBIO, Inc. (0001681087) (Filer)
425 - AVROBIO, Inc. (0001681087) (Subject)
425 - AVROBIO, Inc. (0001681087) (Subject)
425 - AVROBIO, Inc. (0001681087) (Subject)
Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1+ year post-gene therapy in Phase 1/2 clinical triali for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD-02 in Gaucher disease type 1 planned for 2022; third patient dosed in Phase 1/2 clinical trial Regulatory interactions planned in 2022 to inform clinical development and registration strategies for programs in Gaucher disease, cystinosis, Hunter syndrome and Pompe disease Strong balance sheet with cash runway into Q1 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a li
Sustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favorable safety profile with no adverse events related to drug product to date Clinical proof-of-concept in adult patients lays groundwork for AVROBIO-sponsored trial planned to begin in 2023 Analyst and investor conference call scheduled for today at 8:00 a.m. ET AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported
Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022, at 8:00 a.m. ET Five platform presentations and three posters on the company's clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as we
Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str
Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic's novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company expected to have approximately $165 million in cash and cash equivalents at close to provide cash runway into mid-2027 Funding is expected to advance lead asset TX45, a potential best-in-class Fc-relaxin fusion protein, through multiple clinical data catalysts Tectonic's first two programs address indications with high unmet need and no approved therapies Companies to host joint webcast to
On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to initiate late-stage cystinosis clinical trial activities in second half 2023, subject to regulatory alignment Collaborator-sponsored Phase 1/2 clinical trial for mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, initiated Announced appointment of current CFO Erik Ostrowski as interim CEO AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a l
AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean O'Bryan as chief regulatory officer. Sean brings a wealth of experience in regulatory strategy and product development to AVROBIO, as well as keen insight into the field of cell and gene therapy, where he has spent most of his career. "We are delighted to bring Sean O'Bryan on board as we advance multiple programs in lysosomal disorders. His leadership and deep understanding of the cell and gene therapy space will be highly valuable as we progress our clinical programs in cystinosis and Gaucher disease an
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer. Dr. Escolar brings deep expertise across rare diseases, with a focus on lysosomal and neurogenetic disorders. She has been heavily involved in guiding the development of new therapies for rare diseases, including Pompe disease. “We intend to rapidly expand enrollment across our global clinical programs this year, following our multiple strong data readouts in late 2020, as well as continue to plan our regulatory stra
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 85,250 shares of the company’s common stock to three new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options were granted as inducements material to the new employees’ acceptance of employment with the company and were approved by the Compensation Committee of the company’s Board of Directors. The stock opt
SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13G/A - AVROBIO, Inc. (0001681087) (Subject)
SC 13G - AVROBIO, Inc. (0001681087) (Subject)
SC 13G/A - AVROBIO, Inc. (0001681087) (Subject)
SC 13G/A - AVROBIO, Inc. (0001681087) (Subject)
SC 13G/A - AVROBIO, Inc. (0001681087) (Subject)
SC 13G/A - AVROBIO, Inc. (0001681087) (Subject)
SC 13G - AVROBIO, Inc. (0001681087) (Subject)
SC 13G - AVROBIO, Inc. (0001681087) (Subject)